How Investors Are Reacting To New Oriental (EDU) After Goldman Sachs Highlights Its US$5.4 Billion Net Cash
New Oriental Education & Technology Group, Inc. Sponsored ADR EDU | 0.00 |
- Earlier this month, Goldman Sachs upgraded New Oriental Education & Technology Group from Neutral to Buy, highlighting the company’s approximately US$5.40 billion net cash position and expectations for margin expansion in test preparation and livestreaming businesses.
- This reassessment by a major global bank underscores how New Oriental’s substantial cash reserves and improving profitability profile may be reshaping perceptions of its financial resilience.
- Next, we’ll examine how Goldman Sachs’ focus on New Oriental’s sizeable net cash balance could influence the company’s broader investment narrative.
We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
New Oriental Education & Technology Group Investment Narrative Recap
To be a shareholder in New Oriental, you need to believe its pivot into non-academic, test prep and livestreaming can offset regulatory and demographic pressures, while cash returns support sentiment. Goldman Sachs’ upgrade, anchored on the roughly US$5.40 billion net cash balance and potential margin expansion, reinforces that near term catalyst, but does little to reduce the key risk that slower overseas-study demand and tougher competition could still constrain overall growth.
The April 22 earnings release and guidance raise are particularly relevant here. Management lifted full year FY2026 revenue guidance to US$5,561.4 million to US$5,598.7 million, alongside solid Q3 results and ongoing buybacks and dividends. This stronger outlook complements Goldman Sachs’ emphasis on balance sheet strength, suggesting that near term execution in higher margin segments and disciplined capital returns remain central to the investment case while newer ventures in tourism and non academic areas still face execution risk.
Yet despite the upgrade, investors should be aware of how regulatory shifts and demographic pressures could still weigh on New Oriental’s long term earnings trajectory…
New Oriental Education & Technology Group's narrative projects $6.9 billion revenue and $665.7 million earnings by 2029. This requires 8.6% yearly revenue growth and a $245.6 million earnings increase from $420.1 million today.
Uncover how New Oriental Education & Technology Group's forecasts yield a $70.80 fair value, a 52% upside to its current price.
Exploring Other Perspectives
Some of the lowest ranked analysts took a much more cautious view, expecting revenue of about US$6.7 billion and earnings of roughly US$683.9 million by 2029, and highlighting structural market contraction and regulatory pressure as key risks, so it is worth asking whether this latest upgrade and margin optimism will meaningfully shift those more pessimistic expectations over time.
Explore 3 other fair value estimates on New Oriental Education & Technology Group - why the stock might be worth just $54.54!
Decide For Yourself
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your New Oriental Education & Technology Group research is our analysis highlighting 4 key rewards that could impact your investment decision.
- Our free New Oriental Education & Technology Group research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate New Oriental Education & Technology Group's overall financial health at a glance.
Interested In Other Possibilities?
Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:
- The latest GPUs need a type of rare earth metal called Dysprosium and there are only 30 companies in the world exploring or producing it. Find the list for free.
- Find 44 companies with promising cash flow potential yet trading below their fair value.
- AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
